New combo therapy offers hope for Hard-to-Treat blood cancers
NCT ID NCT04640779
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in people with certain blood cancers (lymphoma and multiple myeloma) that came back or didn't respond to previous treatments. The main goal is to find the safest dose and see how well patients tolerate the combination. About 22 adults will take part in this study at the Mayo Clinic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.